Cargando…

Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients

Convalescent plasma (CP) have been used for treatment of coronavirus disease 2019 (COVID-19), but their effectiveness varies significantly. Moreover, the impact of CP treatment on the composition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 patients and anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Juanjie, Grubbs, Gabrielle, Lee, Youri, Golding, Hana, Khurana, Surender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083369/ https://www.ncbi.nlm.nih.gov/pubmed/33861337 http://dx.doi.org/10.1093/cid/ciab317

Ejemplares similares

Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures
por: Ravichandran, Supriya, et al.
Publicado: (2021)

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients
por: Tang, Juanjie, et al.
Publicado: (2021)

Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex
por: Tang, Juanjie, et al.
Publicado: (2021)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
por: Tang, Juanjie, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Vaccinated and Convalescent Donor–Derived Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients
por: Papayanni, Penelope-Georgia, et al.
Publicado: (2021)

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
por: Ravichandran, Supriya, et al.
Publicado: (2020)

Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key
por: Yu, Jiangquan, et al.
Publicado: (2021)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection
por: Choudhary, Manish C, et al.
Publicado: (2021)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study( )
por: Molodtsov, Ivan A, et al.
Publicado: (2022)

Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain
por: Lee, Jeehyun, et al.
Publicado: (2021)

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
por: Etyang, Anthony O, et al.
Publicado: (2021)

Convalescent Plasma Therapy for Coronavirus Disease 2019
por: Choi, Jun Yong
Publicado: (2020)

Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
por: Hartog, Nicholas, et al.
Publicado: (2021)

High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
por: Nkuba, Antoine N, et al.
Publicado: (2021)

Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Magnus, Maria C, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
por: den Hartog, Gerco, et al.
Publicado: (2021)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
por: Bellusci, Lorenza, et al.
Publicado: (2022)

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma
por: Nguyen, Dung, et al.
Publicado: (2021)

Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
por: Grandjean, Louis, et al.
Publicado: (2021)

Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects
por: Duarte, Luisa F, et al.
Publicado: (2023)

Remdesivir and Mortality in Patients With Coronavirus Disease 2019
por: Diaz, George A, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials
por: Levine, Adam C, et al.
Publicado: (2023)

Measurement of Severe Acute Respiratory Syndrome Coronavirus 2 Antigens in Plasma of Pediatric Patients With Acute Coronavirus Disease 2019 or Multisystem Inflammatory Syndrome in Children Using an Ultrasensitive and Quantitative Immunoassay( )
por: Sigal, George B, et al.
Publicado: (2022)

Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection
por: Miyakawa, Kei, et al.
Publicado: (2021)

Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2022)

Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms
por: Cunningham, Janet L, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021
por: Couture, Alexia, et al.
Publicado: (2022)

Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan
por: Hassan, Mozan Osman, et al.
Publicado: (2020)

Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
por: Khatri, Akshay, et al.
Publicado: (2021)

Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing
por: Qureshi, Adnan I, et al.
Publicado: (2021)

Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors
por: Gomaa, Mokhtar R., et al.
Publicado: (2020)

The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Van Vinh Chau, Nguyen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4r26u7926gftjse4j77fa185ue